biomarkers
(8)
Russ Lebovitz
Russ Lebovitz is the co-founder and CEO of Amprion, a precision brain diagnostics company that built the first commercial seed amplification assay for detecting misfolded alpha-synuclein - the protein at the root of Parkinson's disease and other synucleinopathies. An MD/PhD trained at Washington University in St. Louis and a former research physician at Baylor and Fox Chase Cancer Center, Lebovitz spent years chasing prions after the mad cow scare, then pivoted the same detection science toward common neurodegenerative diseases. His SYNTap test won an FDA Breakthrough Device Designation and is now used in clinical trials and patient care to spot brain disease years before symptoms appear.
Rony Sellam
Rony Sellam is the CEO of InsideTracker, a Cambridge, Massachusetts based personalized-health company that uses blood biomarkers, DNA and lifestyle data to give consumers actionable recommendations for extending healthspan. A former Deloitte consultant from France by way of Geneva and a longtime healthcare IT executive, he has run InsideTracker for over a decade and helped push the company past 100,000 members and into partnerships with Oura and Fitness SF.
Bob Wassman
Dr. E. Robert (Bob) Wassman is Chief Medical Officer and Executive Vice President of Clinical Development at MARAbio, a Utah-based diagnostics company building a maternal blood test to identify an autoimmune subtype of autism. A board-certified pediatrician and medical geneticist with more than 40 years in the field, he has served as chief medical officer for a long roster of genetic-testing pioneers including Genzyme Genetics, Ambry Genetics, Rosetta Genomics and Good Start Genetics, repeatedly turning frontier laboratory technology into clinical service across reproductive medicine, cancer, and neurodevelopmental disability.
David Matthews
David Matthews, PhD, is Chief Business Officer at Beacon Biosignals, the computational neurodiagnostics company turning EEG brain data into AI-powered biomarkers for neurological and psychiatric disease. A computational neuroscientist by training, he spent two decades moving between the lab, the boardroom, and the market - from NIH- and NSF-funded research at the Salk Institute to a partnership at Boston Consulting Group to commercial leadership at digital-health platform BrightInsight. He now drives partnerships and commercial growth at a company betting that the brain can be measured at home, at scale.
Dugal Bain-Kim
Dugal Bain-Kim is the co-founder and CEO of Lifeforce, a clinically integrated health optimization platform he launched in February 2022 with Tony Robbins, Dr. Peter Diamandis and Joel Jackson. An Australian-born finance and healthcare operator who went from BlackRock and Cambridge to telehealth, he built Lifeforce after his own fragmented hunt for answers about his changing body at 38. The company tests 40+ biomarkers via at-home blood draws and pairs the data with clinicians, coaching and supplements, on a stated mission to extend healthy lifespan for five million people by 2030.
Mohan Purushothaman
Mohan Purushothaman is the co-founder, chairman, and CEO of Progentec Diagnostics, an Oklahoma City company building blood tests and digital tools that aim to predict autoimmune disease flares before they happen. He came to diagnostics by an unusual route: a Johns Hopkins Ph.D. focused on pharmaceutical pricing, a Harvard research fellowship, five years inside Roche, and a pricing-software practice he built and sold to Alliance Life Sciences. In 2014 he turned that commercial instinct toward lupus, partnering with the Oklahoma Medical Research Foundation, and in 2020 raised a $5M Series A led by Plains Venture Partners to bring the aiSLE DX flare-prediction platform and the LupusCorner patient community to market.
Saad Alam
Saad Alam is the co-founder and CEO of Hone Health, a telehealth platform built around preventative, biomarker-driven longevity care. After a year lost inside the conventional healthcare system, he set out to build the clinic he wished he'd found. Hone now counts hundreds of thousands of tested patients and closed a $33M Series A in early 2025, alongside the acquisition of in-home care company ivee. Before Hone, Alam co-founded the edtech company Citelighter and led market research for Eli Lilly's neuroscience franchise.
Anirudh Joshi
Anirudh Joshi is the co-founder and CEO of Valar Labs, a Palo Alto-based AI oncology company building tools that let doctors predict whether a specific cancer treatment will work before a patient wastes months on the wrong one. A biomedical engineer trained at Georgia Tech and Stanford, he previously built AI at Microsoft, PathAI, and Curai before co-founding Valar in 2021 with teammates from Stanford's AI in Medicine group. Valar raised $26M total, landing a $22M Series A from Andreessen Horowitz and DCVC in 2024, and its flagship test Vesta — predicting BCG therapy response in bladder cancer — is now live at 20 U.S. hospitals. Named to Forbes 30 Under 30 Healthcare 2025.